H3B-8800

Last updated

H3B-8800
H3B-8800.svg
Identifiers
  • [(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-pyridin-2-ylhepta-2,4-dien-2-yl]-1-oxacyclododec-4-en-6-yl] 4-methylpiperazine-1-carboxylate
CAS Number
PubChem CID
Chemical and physical data
Formula C31H45N3O6
Molar mass 555.716 g·mol−1
3D model (JSmol)
  • C[C@H]1/C=C/[C@@H]([C@](CC[C@H](CC(=O)O[C@@H]1/C(=C/C=C/[C@@H](C)C2=CC=CC=N2)/C)O)(C)O)OC(=O)N3CCN(CC3)C
  • InChI=1S/C31H45N3O6/c1-22(26-11-6-7-16-32-26)9-8-10-23(2)29-24(3)12-13-27(39-30(37)34-19-17-33(5)18-20-34)31(4,38)15-14-25(35)21-28(36)40-29/h6-13,16,22,24-25,27,29,35,38H,14-15,17-21H2,1-5H3/b9-8+,13-12+,23-10+/t22-,24+,25-,27+,29-,31-/m1/s1
  • Key:YOIQWBAHJZGRFW-WVRLKXNASA-N

H3B-8800 is an experimental drug which acts as an inhibitor of the SF3B1 protein, which forms part of the splicing factor 3b protein complex. This is commonly mutated in some forms of cancer, principally leukemia but also some subtypes of breast cancer and melanoma. H3B-8800 has reached early stage human clinical trials in patients whose cancers express mutations that make them susceptible to inhibition of SF3B1. [1] [2] [3] [4] [5] [6] [7] [8] [9]


References

  1. ↑ Finci LI, Zhang X, Huang X, Zhou Q, Tsai J, Teng T, et al. (February 2018). "The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action". Genes & Development. 32 (3–4): 309–320. doi:10.1101/gad.311043.117. PMC   5859971 . PMID   29491137.
  2. ↑ Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, et al. (May 2018). "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers". Nature Medicine. 24 (4): 497–504. doi:10.1038/nm.4493. PMC   6730556 . PMID   29457796.
  3. ↑ Zhou Y, Han C, Wang E, Lorch AH, Serafin V, Cho BK, et al. (September 2020). "Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia". Cancer Discovery. 10 (9): 1388–1409. doi:10.1158/2159-8290.CD-19-1436. PMC   7483384 . PMID   32444465.
  4. ↑ Zhang D, Meng F (November 2020). "A Comprehensive Overview of Structure-Activity Relationships of Small-Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents". ChemMedChem. 15 (22): 2098–2120. doi:10.1002/cmdc.202000642. PMID   33037739.
  5. ↑ Sim J, Jang E, Kim HJ, Jeon H (September 2021). "Total Syntheses of Pladienolide-Derived Spliceosome Modulators". Molecules. 26 (19): 5938. doi: 10.3390/molecules26195938 . PMC   8512135 . PMID   34641481.
  6. ↑ Eymin B (July 2021). "Targeting the spliceosome machinery: A new therapeutic axis in cancer?". Biochemical Pharmacology. 189 114039. doi:10.1016/j.bcp.2020.114039. PMID   32417188.
  7. ↑ Spinello A, Borišek J, Malcovati L, Magistrato A (October 2021). "Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers". International Journal of Molecular Sciences. 22 (20) 11222. doi: 10.3390/ijms222011222 . PMC   8540225 . PMID   34681880.
  8. ↑ Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, et al. (December 2021). "Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms". Leukemia. 35 (12): 3542–3550. doi:10.1038/s41375-021-01328-9. PMC   8632688 . PMID   34172893.
  9. ↑ Wheeler EC, Martin BJ, Doyle WC, Neaher S, Conway CA, Pitton CN, et al. (January 2024). "Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML". Science Translational Medicine. 16 (728) eade2774. doi:10.1126/scitranslmed.ade2774. PMC   11222919 . PMID   38170787.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.